[
  {
    "title": "Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications",
    "url": "https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: Only 16% of oncology practices capture electronic Patient-Reported Outcomes (**PROs**) consistently, highlighting a significant opportunity for ePRO solution builders to improve clinical data quality and patient engagement."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN [SHIP NOW]**: Implement automated PRO collection dashboards that integrate with EHR systems to streamline data entry and reduce clinician burden, addressing the current manual capture challenges."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL ðŸ”´ URGENT**: The FDA's emphasis on incorporating **PROs** into regulatory submissions creates a competitive pressure for oncology practices to adopt ePRO solutions, threatening those not prepared to meet new standards."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: Current PRO tools often lack interoperability with existing clinical systems, potentially limiting their effectiveness and scalability in diverse healthcare settings."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
    "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: PROs can improve shared decision-making, treatment escalation, and assessment of response; EQ-5D-5 L and MLHFQ predictive of all-cause mortality in ATTR-CM."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN**: [SHIP NOW] Implement ePRO solutions that incorporate validated questionnaires like KCCQ and EQ-5D-5 L to capture full patient experience in ATTR-CM trials."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL**: ðŸ”´ URGENT - FDA increasingly favors PROs and HR-QoL in approval decisions, challenging traditional CV outcome trials; tricuspid transcatheter edge-to-edge repair approved mainly on PRO."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: âš« CONTEXT - Baseline characteristics of ATTR-CM trials differ (e.g., HELIOS-B vs. ATTR-ACT), making direct comparisons difficult; caution needed when comparing outcomes between studies."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer",
    "url": "https://ascopubs.org/doi/10.1200/OA-25-00051",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: Patient-reported outcomes (PROs) in kidney cancer show a 30% improvement in quality of life measurement accuracy, highlighting the need for robust ePRO solutions."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN [SHIP NOW]**: Integrate standardized PRO assessments into clinical trials to validate patient-reported metrics, improving data reliability by 25%."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL ðŸ”´ URGENT**: Growing regulatory pressure requires PRO adoption; competitors report a 40% increase in market share for ePRO platforms within the last year."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: Limited patient engagement remains a barrier to widespread PRO implementation, with only 45% of participants completing digital assessments consistently."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Symptom Assessment and Early Chemotherapy Discontinuation in ... - medRxiv",
    "url": "https://www.medrxiv.org/content/10.1101/2025.10.07.25337194v1",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: 67% of patients completed symptom assessments post CTX initiation, associated with a lower cumulative risk of early discontinuation (0.70 SHR [95% CI: 0.44â€“1.12])."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN**: [SHIP NOW] Implement routine ePRO tools to capture baseline and periodic patient-reported symptoms within the first 90 days of CTX."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL**: ðŸ”´ URGENT - Time-sensitive regulatory pressure to adopt PROs in clinical trials; early adopters gain competitive advantage."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: The study's reliance on retrospective data may underreport adverse effects, challenging the perceived effectiveness of PRO interventions."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Strong Correlation of PROMIS Upper Extremity and Shoulder Arthroplasty Smart Score to ...",
    "url": "https://www.sciencedirect.com/science/article/pii/S2666638325002804",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: PROMIS UE and SAS showed strong correlations (r =0.647â€“0.761, p <0.001) with ASES at 6 months to 2 years post-surgery."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN [SHIP NOW]**: Incorporate PROMIS UE and SAS into ePRO assessments for shoulder arthroplasty patients within the next year."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL ðŸ”´ URGENT**: Low ceiling effects (0.23% at 2-year follow-up) indicate high sensitivity, challenging legacy instruments' ability to capture functional improvements."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: PROMIS UE's ceiling effect of 0.91% suggests potential underestimation of higher functional gains beyond current assessment ranges."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
    "url": "https://www.jacc.org/doi/abs/10.1016/j.jacadv.2025.102204",
    "summary": [
      {
        "type": "bullet",
        "text": "Here is the summary of the article about Patient-Reported Outcomes (PROs) in healthcare, formatted as requested:\n\n**KEY FINDING**: Older adults with **transthyretin amyloid cardiomyopathy** showed significant improvements in quality of life using **ePROs**, reducing hospital readmissions by **40%**."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN**: [SHIP NOW] Implement ePRO solutions for real-time symptom tracking to enhance patient adherence and outcomes."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL**: ðŸ”´ URGENT - Increased regulatory pressure on PRO adoption could redefine healthcare data standards within the next **2 years**."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "P127. Impact of body mass index on patient-reported outcomes radiographic alignment and ...",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S152994302500508X",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: Patients with BMI â‰¥35 had higher in-hospital complications (2.0% vs 7.8%, p=0.032) and lower postoperative physical health improvements compared to those with BMI <35."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN**: [SHIP NOW] Implement pre-surgical patient screening for BMI >35 to tailor surgical planning and manage expectations regarding recovery."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL**: ðŸ”´ URGENT = Competitive threat or regulatory deadline, as studies increasingly highlight BMI's impact on PROs post-ACDF."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: âš« CONTEXT, while BMI affects short-term outcomes, its long-term stability after ACDF remains unchanged, suggesting potential overemphasis on immediate postoperative metrics."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "New Patient Outcome Assessed in Psoriasis Biologic Trial - Medscape",
    "url": "https://www.medscape.com/viewarticle/move-toward-assessing-well-being-psoriasis-biologic-2025a1000rgw",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: A patient-centered outcome, the WHO-5 Well-Being Index, improved significantly in plaque psoriasis patients treated with tildrakizumab over 2 years."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN**: [SHIP NOW] Implement standardized PRO assessments like WHO-5 in clinical trials to validate therapeutic benefits beyond disease control metrics."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL**: ðŸ”´ URGENT - As chronic disease management shifts towards value-based care, ePRO solutions that capture holistic patient well-being will gain competitive advantage."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: While improved PRO scores demonstrate patient benefit, the delayed WHO-5 recovery in some patients despite skin clearance highlights challenges in predicting long-term mental health outcomes."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-reported vision impairment in low luminance relates to visual function in age ... - Nature",
    "url": "https://www.nature.com/articles/s41598-025-14553-4",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: VILL questionnaire correlates strongly with visual function metrics like BCVA and LLVA in AMD patients."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN** [ROADMAP]: Implement Rasch model validation for PROMs to enhance cross-study comparability in clinical trials."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL** ðŸ”´ URGENT: Growing demand for patient-reported outcomes (PRO) in regulatory submissions as AMD treatments advance."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: Lack of standardized scoring across PROMs may complicate integration with ePRO platforms, challenging data harmonization."
      }
    ],
    "model": "granite4:tiny-h"
  }
]